Avaliação do efeito da enrofloxacina durante a prenhez e no desenvolvimento da prole em ratas

• Autor(a) principal: MELO, Ismaela Maria Ferreira de
• Data de Publicação: 2012
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFRPE
• Texto Completo: http://www.tede2.ufrpe.br:8080/tede2/handle/tede2/4621
• topic: Enrofloxacina; Prenhez; Desenvolvimento placentário; Desenvolvimento fetal; Reprodução animal; Enrofloxacin; Pregnancy; Placental development; Fetal development; Animal reproduction; CIENCIAS AGRARIAS::MEDICINA VETERINARIA

Fluoroquinolones are frequently used in human and veterinary medicine for treatment and prevention of disease respiratory tract, digestive and urinary. Within this group we can highlight the enrofloxacin, a drug that presents a wide spectrum of activity against Gram positive and Gram negative. It is known that fluoroquinolones are the property of crossing the placenta and may have adverse effects on the developing fetus, especially when you consider that more than half of pregnancies are unplanned, and thus a large number of women may be exposed to potentially these drugs during the first trimester of pregnancy. However, the mechanisms of these adverse effects are still unknown. Thus, the present study was to evaluate the effect of enrofloxacin in pregnant rats on placental development and offspring. Enrofloxacin (Baytril ®) was administered at a dose of 5 mg / kg daily intramuscular throughout pregnancy. The placentas were analyzed morphologically, morphometrically and immunohistochemical tests for seven, fourteen and twenty days of pregnancy. The results showed that the treated group there was significant reduction in the number of implantation sites, weight and placental total area of the disk at fourteen and twenty days of development, and quantitative changes in the constituents of the layers of the labyrinth, trophoblastic giant cells and trofospongio of the placenta. There were observed no evidence of malformation in the head, trunk and limbs of neonates. However, there was a significant reduction in the number and weight of neonates in enrofloxacin-treated group compared to control, but without affecting its length. There was no change in the histochemical analysis, however, the TUNEL test showed stronger apoptotic activity in the placentas with only 14 days of development in the treated group compared to control. With this we conclude that enrofloxacin when administered at a dose of 5 mg/kg in rats during pregnancy interferes with placental development by altering the constituents of the placenta and increase apoptosis in the middle third of pregnancy, and reflecting the reduction in the number and weight of neonates.